[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-cancer-face\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-cancer-face":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100610027","comparing-numbing-techniques-in-mohs-micrographic-surgery-100610027",false,"NCT07222241","Comparing Numbing Techniques in Mohs Micrographic Surgery","Randomized, Double-Blind, Placebo-Controlled Trial of Adjunct Nerve Blocks in Mohs Micrographic Surgery on the Face and Scalp","Inclusion Criteria:\n\n* Age ≥18 years.\n* Scheduled to undergo MMS.\n* Lesions on the face or scalp, defined as the region superior to the mandibular margin anteriorly, superior to the external occipital protuberance posteriorly, and superior to the mastoid processes laterally.\n* Tumor diameter plus anticipated stage 1 MMS margin ≥2 cm in diameter OR any tumor on the ear, lip, nose, or eyelid.\n* Ability to complete patient reported outcome measures in English.\n\nExclusion Criteria:\n\n* Known allergy or contraindication to lidocaine or epinephrine.\n* Chronic opioid use or pre existing pain disorders that may interfere with pain reporting.\n* Presence of scar tissue at the anatomic site of local infiltration or nerve block that may alter anesthetic penetration.\n* Concurrent multi site Mohs procedure.\n* Signs of skin and soft tissue infection at the anatomic site of local infiltration or nerve block.\n* Inability to understand or complete pain and satisfaction assessments.\n* Pregnant or breastfeeding.\n* Use of sedatives or anxiolytics prior to the procedure.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study seeks to determine whether adjunct regional nerve blocks reduce pain and anxiety in adult patients undergoing Mohs micrographic surgery for face and scalp skin cancers. Participants will be randomized to one of two arms: (1) placebo regional nerve block with sterile normal saline or (2) adjunct regional nerve block with lidocaine. All patients receive local infiltration with lidocaine for complete anesthesia.",[26,27],"Skin Cancer Face","Skin Cancer Scalp",[29,30],"Mohs","Nerve block","RECRUITING","2026-05-27",{"date":34,"type":35},"2026-05-29","ACTUAL",{"date":37,"type":35},"2026-01-27",{"date":39,"type":20},"2026-07-31",{"name":41,"class":42},"Abramson Cancer Center at Penn Medicine","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100612544","phase-2-capecitabine-prior-to-tumor-resection-in-ent-oncology-capture-100612544","NCT07254962","CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)","CAPTURE","Inclusion Criteria:\n\n* • Previously untreated, histologically confirmed non-HPV related HNSCC and radiologically or histologically confirmed stage I or IVA (AJCC 8th edition).\n\n  * No evidence of distant metastatic disease.\n  * Able to undergo protocol therapy, including necessary imaging and surgery.\n  * If female: may participate if not actively pregnancy nor breastfeeding.\n  * If male: must agree to refrain from donating sperm and must either be abstinent or agree to use contraception.\n  * Performance status (ECOG) of 0, 1 or 2.\n\nExclusion Criteria:\n\n* History of immunodeficiency, HBV, HCV, HIV. No HBV, HCV or HIV testing is required unless mandated by local health authority.\n* Active infection requiring systemic therapy.\n* Previous allogenic tissue\u002Fsolid organ transplant.\n* Known severe hypersensitivity (≥ Grade 3) to capecitabine, its active substance and\u002For any of its excipients.\n* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n* Known DYPD mutation.\n* Known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the trial.\n* Received prior systemic anticancer therapy including investigational agents for the current malignancy prior to allocation.\n* Currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of trial treatment.\n* Known additional malignancy that is progressing or requires active treatment within the past (5 years), excluding basal cell carcinoma or cutaneous squamous cell carcinoma.",{"count":52,"type":20},75,[54],"PHASE2","head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects areas such as the mouth, throat, and voice box. Despite medical progress, little has changed in the care for patients with HPV-negative cancer. The standard care involves surgery followed by radiation or chemotherapy if needed. However, delays in starting treatment - especially beyond six weeks - are linked to worse outcomes. Many patients also experience cancer returning within two years, often making it harder to treat. This study aims to improve outcomes by giving patients a short course of capecitabine, a chemotherapy pill, before surgery. Capecitabine is easier to tolerate than traditional intravenous chemotherapy and has shown promising results in shrinking tumors. Researchers believe that starting this oral treatment early could reduce delays, shrink tumors, make surgery less complex, and improve survival. The clinical trial will randomly assign patients with newly diagnosed stage III or IVa HPV-negative head and neck cancer to receive either standard care or capecitabine before surgery. Surgery will be performed within six weeks of diagnosis, followed by additional therapy as needed. The study will measure how well the tumor responds under the microscope after surgery, how much it shrinks on scans, the safety of the treatment, and cancer-free survival at two years. It will also explore biological markers linked to treatment response.\n\nIf successful, this approach could offer a simpler, faster, and more effective way to treat head and neck cancer, leading to earlier treatment, less invasive surgery, and improved patient outcomes. The study plans to include about 62 patients to evaluate the benefits of this new treatment strategy",[57,58,59,60,26],"Head Neck Cancer","Mouth Cancer","Throat Cancer","Larynx Cancer",[62,63,64,65,66,67],"window of opportunity","surgery","neoadjuvant","capecitabine","Head and neck cancer","HPV-negative","NOT_YET_RECRUITING","2025-11-19",{"date":71,"type":35},"2025-11-28",{"date":73,"type":20},"2026-01-01",{"date":75,"type":20},"2031-01-01",{"name":77,"class":42},"Sir Mortimer B. Davis - Jewish General Hospital",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":43},"100520523","phase-2-tranexamic-acid-in-nasal-mohs-reconstruction-100520523","NCT06057675","Tranexamic Acid in Nasal Mohs Reconstruction","Subcutaneous Tranexamic Acid in Nasal Mohs Local Flap Reconstruction: Perioperative Bleeding, Edema, and Ecchymosis","Inclusion Criteria:\n\n1. Adults at least 18 years of age undergoing local flap reconstruction (bilobe flap, note flap dorsal nasal flap, advancement flap) of a nasal defect following Mohs micrographic surgery. Reconstructive procedures will be performed by Drs. Yang or Patel in the division of Facial Plastic Surgery in the Department of Otolaryngology, Head and Neck Surgery at Vanderbilt University Medical Center.\n2. No other facial plastic procedure or sinus surgery performed simultaneously.\n3. Lack of all the below exclusion criteria.\n\nExclusion Criteria:\n\n1. Known allergy to TXA\n2. Intracranial bleeding\n3. Known defective color vision\n4. History of venous or arterial thromboembolism\n5. History of coagulation disorder\n6. Active thromboembolic disease\n7. Severe renal impairment (diagnosis of chronic kidney disease)\n8. History of acute myocardial infarction\n9. History of stroke\n10. History of seizure\n11. History of liver failure\n12. Preoperative lab results indicating thrombocytopenia (platelets \\\u003C150,000), increased bleeding risk (PT over 45, INR over 1.2).",true,{"count":87,"type":20},100,[54],"This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.",[91,26],"Postoperative Bleeding",[93,94],"Tranexamic Acid","Mohs Reconstruction","2025-08-17",{"date":97,"type":35},"2025-08-19",{"date":99,"type":35},"2024-03-19",{"date":101,"type":20},"2026-06",{"name":103,"class":42},"Vanderbilt University Medical Center"]